RT Journal Article SR Electronic T1 Molecular radiotheranostics for neuroendocrine tumours JF Clinical Medicine JO Clin Med FD Royal College of Physicians SP 462 OP 468 DO 10.7861/clinmedicine.17-5-462 VO 17 IS 5 A1 Shaunak Navalkissoor A1 Glenn Flux A1 Jamshed Bomanji YR 2017 UL http://www.rcpjournals.org/content/17/5/462.abstract AB This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.